|
|
You Are Here
>
>
UA Tests (Urine Drug Test Home Page) >
Drug Information Home Page
> Fentanyl Drug Information
Fentanyl Drug Information, Use, Testing and Treatment
Fentanyl Drug Test
Fentanyl
(also known as fentanil, brand names Sublimaze,
Actiq, Durogesic, Duragesic, Fentora, Onsolis, Instanyl,
Abstral, and others) is a potent synthetic narcotic
analgesic with a rapid onset and short duration of action.
It is a strong agonist at the μ-opioid receptors.
Historically it has been used to treat chronic breakthrough
pain and is commonly used before procedures as an anesthetic
in combination with a
benzodiazepine.
Fentanyl is
approximately 100 times more potent than
morphine, with 100 micrograms of Fentanyl
approximately equivalent to 10 mg of morphine and 75 mg of
pethidine (meperidine) in analgesic activity. It has an LD50
of 3.1 milligrams per kilogram in rats, and an LD50
of 0.03 milligrams per kilogram in monkeys.
Fentanyl was first
synthesized by Dr. Paul Janssen in 1960 following the medical
inception of pethidine several years earlier. Janssen developed
fentanyl by assaying analogues of the structurally-related drug
pethidine for
opioid activity. The widespread use of fentanyl
triggered the production of fentanyl citrate (the salt formed by
combining fentanyl and citric acid in a 1:1 stoichiometry),
which entered the clinical practice as a general anaesthetic
under the trade name Sublimaze in the 1960s. Following this,
many other fentanyl analogues were developed and introduced into
the medical practice, including sufentanil, alfentanil,
remifentanil, and lofentanil.
In the mid 1990s,
fentanyl saw its first widespread palliative use with the
clinical introduction of the Duragesic patch, followed in the
next decade by the introduction of the first quick-acting
prescription formations of fentanyl for personal use, the Actiq
lollipop and Fentora buccal tablets. Through the delivery
method of transdermal patches, fentanyl is currently the
most widely used
synthetic opioid in clinical practice, with several
new delivery methods currently in development.
History
Fentanyl was first
synthesized by Paul Janssen under the label of his relatively
newly formed Janssen Pharmaceutica in 1959. In the 1960s,
fentanyl was introduced as an intravenous anesthetic under the
trade name of Sublimaze. In the mid-1990s, Janssen Pharmaceutica
developed and introduced into clinical trials the Duragesic
patch, which is a formation of an inert alcohol gel infused with
select fentanyl doses which are worn to provide constant
administration of the opioid over a period of 48 to 72 hours.
After a set of successful clinical trials, Duragesic fentanyl
patches were introduced into the medical practice.
Following the patch,
a flavored lollipop of fentanyl citrate mixed with inert fillers
was introduced under the brand name of Actiq, becoming the first
quick-acting formation of fentanyl for use with chronic
breakthrough pain. More recently, fentanyl has been developed
into an effervescent tab for buccal absorption much like the
Actiq lollipop, followed by a buccal spray device for
fast-acting relief and other delivery methods currently in
development.
A new fentanyl
product has been approved by the FDA for breakthrough cancer
pain called Onsolis. It uses a new drug delivery technology
called BEMA (fentanyl buccal soluble film) which is placed in
the mouth on a small disc. There appears to be less abuse
potential because the drug can not be crushed up and snorted
like other fentanyl products.
Mechanism of action
Fentanyl provides
most of its effects typical of other opioids (especially
analgesia, euphoria, and respiratory depression) through
its agonism of the μ-opioid receptors. Its strong potency in
relation to that of morphine is largely due to its high
lipophilicity. Because of this, it can more easily penetrate the
CNS.
Chemistry
Synthesis
The synthesis of
fentanyl (N-phenyl-N-(1-phenethyl-4-piperidinyl)propanamide)
by Janssen Pharmaceutica was achieved in four steps, starting
from 4-piperidinone hydrochloride. The 4-piperidinone
hydrochloride was first reacted with 2-phenylethylbromide to
give N-phenethyl-4-piperidinone (NPP). Treatment of the NPP
intermediate with aniline followed by reduction with sodium
borohydride affording 4-anilino-N-phenethyl-piperidine (ANPP).
Finally ANPP and propionic anhydride are reacted to form the
amide product.
Analogues
The pharmaceutical
industry has developed several analogues of fentanyl:
-
Alfentanil (trade
name Alfenta), an ultra-short-acting (five to 10
minute) analgesic.
-
Sufentanil (trade
name Sufenta), a potent analgesic (five to 10 times
more potent than fentanyl) for use in specific surgeries and
surgery in heavily opioid-tolerant/opioid-dependent patients.
Its binding affinity is high enough to theoretically break
through a
buprenorphine blockade to offer pain relief from
acute trauma in patients who are taking high-dose
buprenorphine.
-
Remifentanil (trade
name Ultiva), currently the shortest-acting opioid, has
the benefit of rapid offset, even after prolonged infusions.
-
Carfentanil (trade
name Wildnil) is an analogue of fentanyl with an
analgesic potency 10,000 times that of morphine and is used in
veterinary practice to immobilize certain large animals such
as elephants.
-
Lofentanil is an
analogue of fentanyl with a potency slightly greater than
carfentanil.
A number of other
fentanyl analogues exist which are classified in the USA as
Schedule I drugs, meaning that they have "no currently accepted
medical use". Many of these drugs have been sold on the street
as "China White". These drugs include:
-
3-Methylfentanyl
(thought to be the active constituent of Kolokol-1, a chemical
weapon)
-
3-Methylthiofentanyl
-
Acetyl-α-methylfentanyl
-
α-methylfentanyl
(see below)
-
α-methylthiofentanyl
-
β-hydroxy-3-methylfentanyl
-
β-hydroxyfentanyl
-
p-flurorofentanyl
-
Thiofentanyl
Therapeutic use
Intravenous fentanyl
is extensively used for anesthesia and analgesia, most often in
operating rooms and intensive care units. It is often
administered in combination with a
benzodiazepine, such as midazolam, to produce
procedural sedation for endoscopy, cardiac catheterization, oral
surgery, etc. Additionally, fentanyl is often used in cancer
therapy and other chronic pain management due to its
effectiveness in relieving pain.

Fentanyl Transdermal System patch (50 µg/h).
It has also been
found to be useful to improve the actions of local anesthetic
during root canal treatment. According to E.A. Elsharrawy in the
Journal of Pain Symptom Management (33; 203-207, 2007), the
intraligamentary injection of 0.4 ml of fentanyl (0.05 mg/ml)
was highly effective in reducing pain when used concurrently
with local anesthetic for a pulpectomy procedure (where the
"hot" nerve is removed).
Fentanyl transdermal
patch (Durogesic/Duragesic/Matrifen) is used in chronic pain
management. The patches work by releasing fentanyl into body
fats, which then slowly release the drug into the bloodstream
over 48 to 72 hours, allowing for long-lasting relief from pain.
The patches are available in generic form and are available for
lower costs. Fentanyl patches are manufactured in five patch
sizes: 12 micrograms/hour, 25 µg/h, 50 µg/h, 75 µg/h, and 100
µg/h. Dosage is based on the size of the patch, since the
transdermal absorption rate is generally constant at a constant
skin temperature. Rate of absorption is dependent on a number of
factors. Body temperature, skin type, amount of body fat, and
placement of the patch can have major effects. The different
delivery systems used by different makers will also affect
individual rates of absorption. The typical patch will take
effect under normal circumstances usually within 8–12 hours,
thus fentanyl patches are often prescribed with another opiate
(such as
morphine or
oxycodone) to handle breakthrough pain.
Fentanyl lozenges
(Actiq) are a solid formulation of fentanyl citrate on a stick
in the form of a lollipop that dissolves slowly in the mouth for
transmucosal absorption. These lozenges are intended for
opioid-tolerant individuals and are effective in treating
breakthrough cancer pain. It is also useful for breakthrough
pain for those suffering bone injuries, severe back pain,
neuropathy, arthritis, and some other examples of chronic
nonmalignant pain. The unit is a berry-flavored lozenge on a
stick which is swabbed on the mucosal surfaces inside the
mouth—inside of the cheeks, under and on the tongue and gums—to
release the fentanyl quickly into the system. It is most
effective when the lozenge is consumed in 15 minutes. The drug
is less effective if swallowed, as despite good absorbance from
the small intestine there is extensive first-pass metabolism,
leading to an oral bioavailability of 33%. Fentanyl lozenges are
available in six dosages, from 200 to 1600 µg in 200 µg
increments (excluding 1000 µg and 1400 µg). These are now
available in the United States in generic form, through an FTC
consent agreement. However, most patients find it takes 10–15
minutes to use all of one lozenge, and those with a dry mouth
cannot use this route. In addition, nurses are unable to
document how much of a lozenge has been used by a patient,
making drug records inaccurate.
Over 2008-09, a wide
range of fentanyl preparations became available, including
buccal tablets or patches, nasal sprays, inhalers and active
transdermal patches (heat or electrical). High-quality evidence
for their superiority over existing preparations is currently
lacking. Some preparations such as nasal sprays and inhalers may
result in a rapid response, but the fast onset of high blood
levels may compromise safety (see below). In addition, the
expense of some of these appliances may greatly reduce their
cost-effectiveness.
On July 16, 2009 the
FDA approved Onsolis (BEMA Fentanyl) for breakthrough cancer
pain. Onsolis incorporates "bioerodible mucoadhesive"
technology, a small soluble film that contains fentanyl which is
placed on the inside cheek of the mouth.
In palliative care,
transdermal fentanyl has a definite, but limited, role for:
-
Patients already
stabilized on other opioids who have persistent swallowing
problem and cannot tolerate other parenteral routes such as
subcutaneous administration.
-
Patients with
moderate to severe renal failure.
-
Troublesome adverse
effects on morphine,
hydromorphone or
oxycodone.
Fentanyl is sometimes
given intrathecally as part of spinal anesthesia or epidurally
for epidural anesthesia and analgesia. Because of fentanyl's
high lipid solubility, its effects are more localized than
morphine and some clinicians prefer to use the morphine to get a
wider spread of analgesia.
Adverse effects
Fentanyl's major side
effects (more than 10% of patients) include diarrhea, nausea,
constipation, dry mouth, somnolence, confusion, asthenia
(weakness), and sweating and, less frequently (3 to 10% of
patients), abdominal pain, headache, fatigue, anorexia and
weight loss, dizziness, nervousness, hallucinations, anxiety,
depression, flu-like symptoms, dyspepsia (indigestion), dyspnea
(shortness of breath), hypoventilation, apnea, and urinary
retention. Fentanyl use has also been associated with aphasia.
Despite being a more
potent analgesic, fentanyl tends to induce less nausea, as well
as less histamine-mediated itching, in relation to morphine.
The fentanyl patch
has been associated with altered mental state leading to
aggression in an anecdotal case report.
Like other
lipid-soluble drugs, the pharmacodynamics of fentanyl are poorly
understood. The manufacturers acknowledge there is no data on
the pharmacodynamics of fentanyl in elderly, cachectic or
debilitated patients, frequently the type of patient for whom
transdermal fentanyl is being used. This may explain the
increasing number of reports of respiratory depression events
since the late 1970s. In 2006 the U.S. Food and Drug
Administration began investigating several respiratory deaths,
but doctors in the United Kingdom had to wait until September
2008 before being warned of the risks with fentanyl.
The precise reason
for sudden respiratory depression is unclear, but there are
several hypotheses:
-
Saturation of the
body fat compartment in patients with rapid and profound body
fat loss (patients with cancer, cardiac or infection-induced
cachexia can lose 80% of their body fat).
-
Early carbon
dioxide retention causing cutaneous vasodilatation (releasing
more fentanyl), together with acidosis which reduces protein
binding of fentanyl, releasing yet more fentanyl.
-
Reduced sedation,
losing a useful early warning sign of opioid toxicity and
resulting in levels closer to respiratory depressant levels.
Fentanyl has a
therapeutic index of 270.
Illicit use

Fentanyl powder seized by a Lake County Deputy Sheriff in
Painesville, Ohio, where a male subject had been discovered
unresponsive and struggling to breathe.
Buy Fentanyl Drug Test
Illicit use
of pharmaceutical fentanyl first appeared in the mid-1970s in
the medical community and continues in the present. United
States authorities classify fentanyl as a
narcotic. To date, more than 12 different analogues
of fentanyl have been produced clandestinely and identified in
the U.S. drug traffic. The biological effects of the fentanyls are similar to those of
heroin, with the exception that many users report a noticeably
less euphoric "high" associated with the drug and stronger
sedative and analgesic effects.
The use of fentanyl
has caused death. Because the effects of fentanyl last for only
a very short time, regular users may become addicted very
quickly. Additionally, fentanyl may be hundreds of times more
potent than
street heroin, and tends to produce significantly
worse respiratory depression, making it somewhat more dangerous
than heroin to users. Fentanyl is most commonly used orally, but
like heroin, can also be smoked, snorted or injected. Fentanyl
is sometimes sold as heroin, often leading to overdoses. Many
fentanyl overdoses are initially classified as heroin overdoses.
Fentanyl is normally
sold on the black market in the form of transdermal fentanyl
patches such as Duragesic, diverted from legitimate medical
supplies. The patches may be cut up and eaten, or the gel from
inside the patch smoked. To prevent the removal of the fentanyl
base, Janssen--Cilag, the inventor of the Fentanyl patch,
designed the Durogesic patch. The Durogesic patches contain
their fentanyl throughout the plastic matrix instead of gel
incorporated into a reservoir on the patch. Manufacturers such
as Mylan and Sandoz have also produced Durogesic-style fentanyl
patches that contain the chemical in a silicone matrix,
preventing the removal of the fentanyl-containing gel present in
other products. The plastic matrix makes the patches far less
suitable to transbuccal use and far more difficult to use
illicitly than its gel-filled counterpart.
Another dosage form
of fentanyl that has appeared on the streets are the Actiq
fentanyl lollipops, which are sold under the street name of "percopop".
The pharmacy retail price ranges from US$10 to US$30 per unit
(based on strength of lozenge), with the black market cost
anywhere from US$15 to US$40 per unit, depending on the
strength.
Non-medical use of fentanyl by individual without
opiate tolerance can be very dangerous and has
resulted in numerous deaths. Even those with opiate tolerances
are at high risk for overdoses. Once the fentanyl is in the
user's system it is extremely difficult to stop its course
because of the nature of absorption. Illicitly synthesized
fentanyl powder has also appeared on the United States market.
Because of the extremely high strength of pure fentanyl powder,
it is very difficult to dilute appropriately, and often the
resulting mixture may be far too strong and, consequently, very
dangerous.
Some heroin dealers mix fentanyl powder with heroin to increase
potency or compensate for low quality
heroin. In 2006, illegally manufactured,
non-pharmaceutical fentanyl often mixed with
cocaine or heroin caused an outbreak of overdose
deaths in the United States, heavily concentrated in the cities
of Chicago, Detroit, and Philadelphia. Baltimore, Pittsburgh,
St. Louis, Milwaukee, Camden, New Jersey, Little Rock, and
Dallas were also affected. The mixture of fentanyl and heroin is
known as "magic" or "the bomb," among other names, on the
street.
Several large quantities of illicitly produced fentanyl have
been seized by U.S. law enforcement agencies. In June 2006, 945
grams of 83% pure fentanyl powder was seized by Border Patrol
agents in California from a vehicle which had entered from
Mexico. Mexico is the source of much of the illicit fentanyl for
sale in the U.S. However, in April 2006 there was one domestic
fentanyl lab discovered by law enforcement in Azusa, California.
The lab was a source of counterfeit 80-mg
OxyContin tablets containing fentanyl instead of
oxycodone, as well as bulk fentanyl and other drugs.
The "China White"
form of fentanyl refers to any of a number of clandestinely
produced analogues, especially α-methylfentanyl (AMF). This
Department of Justice document lists "China White" as a synonym
for a number of fentanyl analogues, including 3-methylfentanyl
and α-methylfentanyl, which today are classified as Schedule I
drugs in the United States. Part of the motivation for AMF is
that despite the extra difficulty from a synthetic standpoint,
the resultant drug is relatively more resistant to metabolic
degradation. This results in a drug with an increased duration.
Military use
A derivative of
fentanyl may have been used as the Moscow hostage crisis
chemical agent.
The Danish Army is
also using the fentanyl stick in military operations as a pain
killer.
United States Air
Force Pararescue uses lollipops with fentanyl.
Overdoses, recalls,
and legal action
A number of fatal
fentanyl overdoses have been directly tied to the drug over the
past several years. In particular, manufacturers of time-release
fentanyl patches have come under scrutiny for defective
products. While the fentanyl contained in the patches was safe,
a malfunction of the patches caused an excessive amount of
fentanyl to leak and become absorbed by patients, resulting in
life-threatening side effects and even death.
Manufacturers of
fentanyl transdermal pain patches have voluntarily recalled
numerous lots of their patches, and the U.S. Food and Drug
Administration (FDA) has issued public health advisories related
to fentanyl patch dangers. Manufacturers affected include
Janssen Pharmaceutica Products, L.P.; Alza Corporation; Actavis
South Atlantic, LLC; Sandoz; and Cephalon, Inc.
On May 24, 2009,
Wilco's former guitarist Jay Bennett died in his sleep of an
overdose of the drug via Duragesic time-release patches, which
he was prescribed.
In 2010, Slipknot's
bassist Paul Gray died after accidentally overdosing on a
mixture of fentanyl and morphine, after struggling with
substance abuse problems for many years.
An inquest jury found
by a majority verdict of 3-2 that an overdose of fentanyl was
responsible for the death by misadventure of Anita Chan
Lai-ling, 69, who died on October 17, 2007, after she was given
an overdose of the powerful fentanyl.
|